24th Annual International Congress on the Future of Breast Cancer® West 

Breakfast and Non‐CE Product Theater: Addressing the Needs of Patients Across the HR+/HER2‐ Landscape

Welcome, Introductions, and Presession Survey

Immunotherapy for High-Risk Early-Stage Breast Cancer: Who Benefits?

Systemic Therapy for Premenopausal HR+ Early Breast Cancer

Optimization of IO for Early Stage Breast Cancer

Evolving HER2-Directed Therapy for Early Breast Cancer

Which CDK4/6 Inhibitor for Which HR+ HER2-Early Breast Cancer Patients?

Is There Any Clinical Utility in Monitoring for Molecular Residual Disease in EBC?

DEBATE: Surgery First or Neoadjuvant Therapy for HER2+ and TN T1cN0 Early Breast Cancer

Controversial Cases in EBC: Who Benefits From Anthracycline, CDK4/6 Inhibitors, Immunotherapy, PARP Inhibitors, and Neoadjuvant Therapy

Lunch and Non‐CME Product Theater: Treatment Considerations for Patients With HR+/HER2‐mBC, Including Patients ≥65 Years of Age

Updates on CDK4/6 Inhibitors for Metastatic Breast Cancer

Targeting ER and Mutant ER in Metastatic Breast Cancer

How and When to Inhibit the PI3K/AKT Pathway

Current and Future Landscape of Antibody Drug Conjugates

New Therapeutic Strategies for HER2+ Metastatic Disease

What is new in Molecular Imaging for Patients with Breast Cancer

Controversial Cases in MBC: Sequencing Inhibitors of CDK4/6, ESR1, PI3K/AKT, and ADCs

Breast Cancer Tumor Board: Targeting TROP2 - Innovations in Triple-Negative Breast Cancer Treatment (Spotlight CE Session)

Breakfast and Non‐CE Product Theater: Peer Insights to Help Identify and Manage Candidates for Treatment With a CDK4/6 Inhibitor

Active Monitoring of DCIS: What Are the Pros and Cons?

Who Needs More, Less, or No Axillary Lymph Node Surgery?

Endocrine Therapy vs Radiation Therapy vs Both in Postmenopausal Breast Cancer

New Techniques for Reducing Surgical Morbidity From Breast and Axillary Surgery

Prophylactic Surgery in BRCA Mutation Carriers With Breast Cancer: What Are the Outcomes?

Postmastectomy Radiation Therapy: Where Are We?

Evaluation and Management of the Axilla After Neoadjuvant Chemotherapy: Current Best Practices

New Approaches in Breast Radiotherapy De-Escalation

Case Discussions From Faculty Practices/Q&A Session

Lunch and Non‐CME Product Theater: New Treatment Option in HER2‐Expressing mBC

Management of Endocrinopathies from Immunotherapy

Management of Endocrine Therapy-Resistant MBC Guided by ctDNA

Evolution of Insights From the I-SPY Trials

Weight Loss, Incretin-Mimetics, and Breast Cancer Outcome